Among the three foundational criteria that a patent applicant must satisfy to obtain a grant novelty, inventive step and industrial applicability industrial applicability is perhaps the least litigated and the least theoretically contested, yet it performs an indispensable function in defining the outer boundary of the patent system’s reach. It is the criterion that ensures patents are granted only for inventions that have a concrete, practical utility in the world of human productive activity not for abstract theories, speculative proposals or intellectual constructs that exist only in the imagination of their creators. In doing so, it anchors the patent system firmly in its utilitarian justification: the grant of a temporary monopoly in exchange for a contribution to useful knowledge that society can actually exploit.
In India, industrial applicability is codified as a patentability requirement under the Patents Act, 1970. It operates alongside novelty under Section 2(1)(l) and inventive step under Section 2(1)(ja) to constitute the complete substantive framework for patentability. An invention that is novel and involves an inventive step but lacks industrial applicability cannot be patented. Conversely, an invention that is industrially applicable but lacks novelty or inventive step is equally unpatentable. All three criteria must be independently satisfied and the failure of any one is fatal to the application.
This article examines industrial applicability in depth its statutory definition, its theoretical foundations, its relationship with the allied concept of utility in other patent systems, its application in Indian examination and judicial practice and the categories of invention that most frequently engage it. It also addresses the interaction between industrial applicability and the exclusions from patentability under Section 3 of the Act, an interaction that is practically significant and often misunderstood.
The Statutory Definition – Section 2(1)(ac)
Industrial applicability is defined in Section 2(1)(ac) of the Patents Act, 1970, which provides that “industrially applicable”, in relation to an invention, means that the invention is capable of being made or used in an industry. The definition is notable for its brevity. Parliament did not elaborate on what constitutes an industry, did not specify the degree of applicability required and did not distinguish between different categories of industrial use. The definition is framed in terms of capability the invention need not have been made or used in industry; it must be capable of being so made or used.
The word “industry” in Section 2(1)(ac) is to be understood in its broad, non-technical sense. It encompasses manufacturing, agriculture, commerce, services and any other organized field of human productive or economic activity. It is not confined to factory-based production or to heavy industrial processes. A pharmaceutical compound capable of treating a disease is industrially applicable because it can be made and used in the pharmaceutical industry. A software algorithm with a specific technical application is industrially applicable because it can be used in the information technology industry. An agricultural method that improves crop yield is industrially applicable because it can be used in agriculture. The breadth of the definition reflects the patent system’s intention to reward useful innovation across all fields of technology.
The Theoretical Foundation – Why Industrial Applicability Matters
The requirement of industrial applicability reflects a foundational policy judgment about the proper scope of the patent system. Patents are not awarded for knowledge in the abstract. They are awarded for inventions for practical, concrete contributions to the useful arts that advance human productive capacity. An invention that cannot be made or used in any industry, however intellectually brilliant it may be, makes no contribution to productive capacity and therefore does not justify the grant of a monopoly that restricts the freedom of others to operate.
This policy judgment is embedded in the TRIPS Agreement, which requires member states to make patents available for inventions in all fields of technology, provided they are new, involve an inventive step and are capable of industrial application. Article 27(1) of TRIPS expressly includes industrial applicability as a required patentability criterion and India’s adoption of Section 2(1)(ac) reflects compliance with this international obligation.
The theoretical importance of industrial applicability is most clearly visible at the margins – in cases involving purely scientific discoveries, mathematical theories, abstract methods and speculative proposals. A scientist who discovers a new physical constant has made a profound intellectual contribution but has not invented anything industrially applicable. A mathematician who develops a new theorem has advanced human knowledge but has not created something that can be made or used in industry. These contributions are celebrated and rewarded through other mechanisms academic recognition, prizes, grants but not through patent protection, because the patent system is reserved for contributions with practical industrial utility.
Industrial Applicability and Section 3 Exclusions – The Relationship
One of the most important aspects of industrial applicability in Indian patent law is its relationship with the exclusions from patentability under Section 3 of the Patents Act, 1970. Section 3 lists a range of subject matter that is not an invention for the purposes of the Act – discoveries, scientific theories, mathematical methods, business methods, computer programmes per se, methods of treatment of the human or animal body and several others. Many of the categories excluded under Section 3 are also categories that would fail the industrial applicability test, but the two analyses are not identical and the relationship between them requires careful attention.
Section 3 exclusions are categorical -they remove specified categories of subject matter from the scope of patentable inventions entirely, regardless of whether those categories might in some formulation satisfy the industrial applicability test. A method of treatment of the human or animal body, excluded under Section 3(i), might in principle be characterized as having industrial applicability – it can be used in the medical industry. But Section 3(i) excludes it regardless, on the separate policy ground that methods of medical treatment should be freely available to medical practitioners and should not be encumbered by patent monopolies.
The industrial applicability requirement, by contrast, is not a categorical exclusion of any subject matter – it is a positive requirement that all inventions must satisfy. Its function is to exclude from patentability inventions that are inherently incapable of practical application, rather than inventions that fall within a designated category. The two analyses are therefore complementary. Section 3 asks: is this subject matter within a category that Parliament has decided to exclude from patentability? Section 2(1)(ac) asks: even if this subject matter is not categorically excluded, does it have the practical industrial utility that the patent system requires?
In practice, however, there is significant overlap. A purely abstract mathematical method fails both Section 3(k) – as a mathematical method and the industrial applicability test – as something that cannot be made or used in any industry. A business method fails Section 3(k) – as a business method – and may also fail industrial applicability if it has no concrete industrial implementation. The examiner at the Indian Patent Office may raise both objections in respect of the same invention and the applicant must address both.
Capable of Being Made or Used – The Capability Standard
The definition in Section 2(1)(ac) requires that the invention be capable of being made or used in an industry. The word “capable” introduces a standard of possibility rather than actuality. The invention need not have been reduced to practice, need not have been commercially exploited and need not have been manufactured or used by anyone. It must be capable – in the sense that it is possible, in principle, to make or use it in an industrial context.
This capability standard has two important consequences. First, it means that an invention can satisfy the industrial applicability requirement even if the technology needed to exploit it does not yet fully exist, provided that the specification discloses a credible pathway to industrial use that a person skilled in the relevant field would accept as feasible. A pharmaceutical compound for which a synthesis route is described in the specification and which shows pharmacological activity in laboratory tests, satisfies industrial applicability even if it has not yet entered clinical trials or been commercially manufactured.
Second, the capability standard means that an invention that is described in entirely speculative or theoretical terms – without a credible account of how it could be made or used in practice – does not satisfy industrial applicability. A mere assertion that an invention could, in principle, have some industrial application is insufficient. The specification must disclose enough about the invention’s practical implementation to establish that industrial use is genuinely possible, not merely hypothetically conceivable.
The Indian Patent Office’s Manual of Patent Office Practice and Procedure addresses this point by directing examiners to assess whether the specification contains sufficient information to establish industrial applicability – specifically, whether a person skilled in the art would understand from the specification how the invention is to be made or used in an industrial context. Where the specification is silent on practical implementation or where it describes the invention at a level of abstraction that precludes any concrete industrial use, an objection under Section 2(1)(ac) is properly raised.
The Sufficiency of Disclosure – The Link Between Industrial Applicability and Specification Requirements
The industrial applicability requirement is closely connected to the sufficiency of disclosure requirement under Section 10(4) of the Patents Act, 1970. Section 10(4) requires that the complete specification shall fully and particularly describe the invention and its operation or use and the method by which it is to be performed and shall disclose the best method of performing the invention which is known to the applicant. This requirement of full disclosure is, in part, the mechanism through which industrial applicability is established.
An invention that is industrially applicable must, by definition, be capable of being made or used in industry. A specification that does not explain how the invention is to be made or used – that claims a result without disclosing a method or that describes a product without explaining how it is manufactured – fails both the sufficiency requirement and, in many cases, the industrial applicability requirement simultaneously. The two requirements reinforce each other and an objection framed in terms of industrial applicability will frequently also engage the sufficiency of disclosure analysis.
The Delhi High Court addressed the relationship between industrial applicability and disclosure sufficiency in Dimminaco A.G. v. Controller of Patents & Designs ((2002) IPLR 255 Cal), where the Court considered whether a process for preparing a live vaccine was patentable, examining both the industrial applicability of the process and the sufficiency of the specification’s disclosure of the method by which it was to be performed. The Court’s analysis demonstrates the practical interconnection between the two requirements and the importance of a specification that clearly articulates the industrial context and mode of use of the invention.
Industrial Applicability in Pharmaceutical and Biotechnology Inventions
The pharmaceutical and biotechnology sectors present some of the most complex and practically significant industrial applicability questions in Indian patent law. These are sectors where the gap between basic research – the discovery of a new compound, a new biological target or a new genetic sequence and commercially viable industrial application is often wide and where the question of whether a claimed invention crosses the threshold of industrial applicability is frequently contested.
For pharmaceutical compounds, the industrial applicability requirement generally demands that the specification disclose a specific, credible and substantial therapeutic use. A compound for which no therapeutic application is identified or for which only a speculative or hypothetical therapeutic application is suggested, does not satisfy industrial applicability. The specification must identify a disease or condition that the compound treats, explain the mechanism or basis for that treatment with sufficient credibility, and, ideally, provide experimental data demonstrating the therapeutic effect whether in vitro, in animal models or in clinical settings.
The requirement of a specific and credible utility reflects the concern that broad claims over classes of compounds with no demonstrated therapeutic application would allow patent applicants to stake out large areas of chemical or biological space on the basis of speculation, blocking subsequent researchers from exploring those areas without any countervailing contribution to useful knowledge. The industrial applicability criterion, strictly applied, prevents this outcome by requiring applicants to identify and disclose a concrete industrial use before the monopoly is granted.
In F. Hoffmann-La Roche Ltd. & Anr. v. Cipla Ltd. ((2008) 36 PTC 1 (Del)), the Delhi High Court examined patentability questions in the pharmaceutical context, addressing among other things the relationship between the claimed invention and its therapeutic application. While the decision is primarily known for its analysis of the Section 3(d) enhanced efficacy requirement, its reasoning touches on the broader framework of utility and industrial applicability as applied to pharmaceutical compounds, confirming that a clear therapeutic application is essential to the patentability of such compounds in India.
For biotechnology inventions particularly those involving genetic sequences, proteins and biological materials the industrial applicability question is similarly demanding. A newly identified gene sequence is a discovery and a discovery is not an invention under Section 3(c) of the Act. To cross the threshold from non-patentable discovery to patentable invention, the applicant must identify a specific, credible industrial application for the sequence a protein it encodes, a diagnostic test it enables, a therapeutic target it represents. Without that identification, the claim remains in the territory of the unpatentable discovery.
The European Patent Office’s technical board of appeal decisions on biological materials and gene sequences particularly the line of cases addressing expressed sequence tags and gene fragments have influenced Indian examination practice in this area, providing guidance on the level of specificity required to establish industrial applicability for biotechnological inventions. Indian examiners and practitioners have drawn on this jurisprudence in the absence of authoritative domestic guidance, reflecting the broad convergence of patent examination standards across major jurisdictions in this technically complex field.
Industrial Applicability and Agricultural Inventions
Agricultural inventions new plant varieties, improved cultivation methods, soil treatment processes and pest control techniques present industrial applicability questions that are distinct from those arising in the pharmaceutical and technology sectors. Agriculture is an industry within the meaning of Section 2(1)(ac) and inventions that improve agricultural productivity or efficiency are capable of being used in that industry.
However, Section 3(h) of the Patents Act, 1970 excludes from patentability a method of agriculture or horticulture. This exclusion interacts with the industrial applicability requirement in a way that can be confusing. A method of agriculture is, by definition, applicable in the agricultural industry it satisfies the industrial applicability criterion. But it is excluded from patentability by Section 3(h) regardless of its industrial applicability. The Section 3(h) exclusion thus operates independently of and in addition to the industrial applicability requirement, removing from patentable subject matter a category of invention that would otherwise satisfy Section 2(1)(ac).
The exclusion of methods of agriculture from patentability reflects a policy judgment that agricultural methods should remain freely available to farmers, who depend on access to cultivation techniques for their livelihoods. It is a social policy exclusion, not a substantive patentability exclusion and its existence underscores the importance of analyzing Section 3 separately from the Section 2(1)(ac) industrial applicability requirement.
Industrial Applicability and Computer-Related Inventions
In the context of computer-related inventions and artificial intelligence an area of increasing importance before the Indian Patent Office the industrial applicability requirement operates in conjunction with Section 3(k), which excludes computer programmes per se, mathematical methods and algorithms from patentable subject matter. An AI or software invention that is claimed in purely abstract terms as a mathematical model, an algorithm or a programme divorced from any specific industrial application fails both Section 3(k) and the industrial applicability requirement.
Where, however, an AI or software invention is framed as a technical system solving a specific technical problem in a defined industrial field a computer-implemented method for optimizing the operation of a power grid, a machine-learning system for detecting malignancies in medical imaging or an algorithm embedded in an autonomous vehicle’s control system the industrial applicability requirement is satisfied. The invention has a concrete industrial application in the energy sector, the medical sector or the automotive sector respectively and the specification discloses how that application is implemented.
The interaction between industrial applicability and Section 3(k) in the context of computer-related inventions was addressed in the context of the CRI Guidelines issued by the Indian Patent Office in 2017, which direct examiners to assess whether a computer-related invention has a technical effect beyond the normal interactions between software and hardware. An invention with a qualifying technical effect has, by implication, an industrial application the technical effect is the industrial utility. An invention without such a technical effect fails both Section 3(k) and the industrial applicability requirement, though the Section 3(k) exclusion is typically the primary ground of rejection.
Comparison with the Utility Requirement in United States Patent Law
A comparative perspective on industrial applicability is illuminating, particularly a comparison with the utility requirement in United States patent law under 35 U.S.C. § 101. The utility requirement in American law demands that an invention have a specific, substantial and credible utility a formulation developed through examination guidelines and judicial decisions that closely parallels the Indian industrial applicability standard, despite the different statutory language.
The United States Court of Appeals for the Federal Circuit’s decision in In re Fisher (421 F.3d 1365, Fed. Cir. 2005) addressed the utility requirement in the context of expressed sequence tags — short genetic sequences of uncertain function and held that a bare assertion that a sequence might have some future research utility, without identification of a specific and substantial utility in the present, did not satisfy the utility requirement. The reasoning of this decision resonates with the Indian industrial applicability standard, which similarly requires a concrete, presently realizable industrial use rather than a speculative future application.
The European Patent Convention, in Article 57, uses language almost identical to Section 2(1)(ac) it requires that an invention be susceptible of industrial application, meaning that it can be made or used in any kind of industry. EPO examination practice under Article 57 has developed a body of guidance on the industrial applicability of biotechnological inventions, pharmaceutical compounds and software-related inventions that has been influential in shaping Indian examination practice, particularly in areas where domestic precedent is limited.
Examination Practice – How Industrial Applicability Objections Arise
In the daily practice of the Indian Patent Office, industrial applicability objections arise most commonly in four categories of application: applications for purely abstract or theoretical inventions, applications for pharmaceutical or biotechnological compounds without identified therapeutic utility, applications for computer-related inventions that lack a concrete technical application and applications that are so broadly drafted as to encompass subject matter that extends beyond any industrially applicable use.
The last category over-broad claims is particularly important. An applicant who drafts claims at a level of generality that extends beyond the industrial application disclosed in the specification risks an objection not only under the sufficiency requirements of Section 10(4) but also under the industrial applicability requirement. A claim to “a compound capable of treating any disease” when the specification discloses only a specific treatment for a specific disease is broader than any industrially applicable use that has been demonstrated and the industrial applicability objection in such a case is directed at the mismatch between the scope of the claim and the scope of the demonstrated utility.
The examiner’s assessment of industrial applicability is guided by the Manual of Patent Office Practice and Procedure, which directs examiners to consider whether the description in the specification is such that a skilled person could carry out the invention and whether the invention can be practically applied to the production of goods or to the provision of services in any industry. Where the answer to either question is negative, an objection under Section 2(1)(ac) should be raised in the First Examination Report.
The Prospective Industrial Application — Future Technologies
A nuanced question arises in the context of inventions that are industrially applicable not at the time of filing but in the future – inventions that depend on technologies or industrial capacities that do not yet exist at the filing date but that are foreseeable developments of the state of the art. The capability standard in Section 2(1)(ac) – capable of being made or used raises the question of whether capability at a future date satisfies the requirement.
The better view, consistent with the approach taken by major patent offices, is that the industrial applicability must exist at the filing date or must be sufficiently foreseeable as of that date that a person skilled in the art would regard the industrial application as achievable within a reasonable time frame. An invention whose industrial application depends on a technological breakthrough that has not yet occurred and that cannot reasonably be predicted does not satisfy industrial applicability at the time of filing, regardless of what might become possible in the future.
This principle prevents speculative patent applications from blocking future inventors who actually develop the technology needed to realize the claimed application. It ensures that the patent monopoly is granted in exchange for a genuine, present contribution to industrial knowledge, not a bet on future technological development.
Conclusion
Industrial applicability, as defined in Section 2(1)(ac) of the Patents Act, 1970 and required by Article 27(1) of the TRIPS Agreement, is the patentability criterion that grounds the patent system in practical utility. By requiring that every patentable invention be capable of being made or used in an industry, it ensures that patent protection is reserved for concrete contributions to human productive capacity, not for abstract theories, speculative proposals or intellectual constructs without practical application.
The criterion’s importance is greatest at the margins of patentable subject matter in pharmaceutical and biotechnological research, in artificial intelligence and software innovation, in basic scientific research that has not yet been translated into practical application and it is in these areas that examination practice and judicial interpretation will continue to develop as Indian innovation extends further into these frontier territories.
For applicants, the industrial applicability requirement demands that every patent specification clearly identify the industrial context of the invention, explain how it is to be made or used in that context and provide sufficient experimental or demonstrative support for the claimed utility. An application that satisfies these requirements will present no difficulty on industrial applicability grounds. An application that relies on assertion without demonstration, on speculation without evidence or on abstract description without practical implementation will face objections that, if sustained, are fatal to the grant.
The requirement is, in its essence, a statement of the patent system’s fundamental bargain monopoly in exchange for useful knowledge. Industrial applicability is the mechanism through which the “useful” part of that bargain is enforced.
References
- The Patents Act, 1970, Section 2(1)(ac) — https://ipindia.gov.in/writereaddata/Portal/IPOAct/1_31_1_patent-act-1970-11march2015.pdf
- Manual of Patent Office Practice and Procedure, Indian Patent Office — https://ipindia.gov.in/writereaddata/Portal/IPOGuidelinesManuals/1_81_1_patent-manual-2019.pdf
- Guidelines for Examination of Biotechnology Applications for Patents, Indian Patent Office — https://ipindia.gov.in/writereaddata/Portal/IPOGuidelinesManuals/1_77_1_Biotech_Guidelines.pdf
- Guidelines for Examination of Computer Related Inventions, 2017 — https://ipindia.gov.in/writereaddata/Portal/IPOGuidelinesManuals/1_73_1_CRI_Guidelines_August_2015.pdf
- Dimminaco A.G. v. Controller of Patents & Designs, (2002) IPLR 255 (Cal)
- F. Hoffmann-La Roche Ltd. & Anr. v. Cipla Ltd., (2008) 36 PTC 1 (Del)
- In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005)
- TRIPS Agreement, Article 27 — https://www.wto.org/english/docs_e/legal_e/27-trips.pdf
- European Patent Convention, Article 57 — https://www.epo.org/law-practice/legal-texts/epc.html
- EPO Guidelines for Examination, Part G, Chapter III — https://www.epo.org/law-practice/legal-texts/guidelines.html
- WIPO — Standing Committee on the Law of Patents — https://www.wipo.int/scp/en/